1Caprlllm R, Vlscldo A, Latella G. Current management of se- vere ulcerative colilis [J]. Nat Clinl Pract Gastroenterol Hepa tol, 2007, 4(2): 92-101.
2Bbirivant M, Fuss IJ, Chu A,etal. Oxazolone colitis.. A mu- rine model of Thelper cell type 2 colitis treatable with antibod-to Interleukin 4 [J]. J Exp Med, 1998, 188:1929-1939.
3eller F, Fuss I J, Nieuwenhuis EE,et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13 producing NK T cells [J]. Immunity, 2002, 17 (5):629-638.
4Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ul- cerative colitis in mice [J]. Gastroenterology, 1990, 98:694-702.
5EkstrmGM. Oxazolone-induced colitis in rats: effects of budesonide, eyclosporin A, and 5-aminosalicylic acid [J].Scand J Gastroenterol, 1998, 33:174-179.
6Akazawa A, Sakaida I, Higaki S, et al. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase [J]. Gastroenterol, 2002, 37(5): 345-353.
7Klein W, Tromm A, Griga T, et al. Interleukin-4 and inter- leukin-4 receptor gene polymorphisms in inflammatory bowel diseases[J]. Genes Immun, 2001, 2:287-289.
